metaEvidence

	atezolizumab based treatment	avelumab based treatment	durvalumab based treatment	durvalumab alone	nivolumab based treatment	pembrolizumab alone		anti-PD-(L)1
	atezolizumab alone	avelumab alone	durvalumab alone	durvalumab plus osimertinib	nivolumab alone	pembrolizumab (10mg/kg)	pembrolizumab (2mg/kg)	Tislelizumab
mNSCLC - L2 - adenocarcinoma cell
mNSCLC - L2 - all population 5
mNSCLC - L2 - EGFR high
mNSCLC - L2 - EGFR mutant 1
mNSCLC - L2 - EGFR wild type
mNSCLC - L2 - KRAS mutant
mNSCLC - L2 - KRAS wild type
mNSCLC - L2 - PDL1 negative 1
mNSCLC - L2 - PDL1 positive 7
non squamous cell - mNSCLC - L2
non squamous - mNSCLC - L2 - all population 1
non squamous - mNSCLC - L2 - EGFR mutant
non squamous - mNSCLC - L2 - PDL1 positive
non squamous - mNSCLC - L2 - wild type (WT)
squamous cell - mNSCLC - L2
squamous - mNSCLC - L2 - all population 1
squamous - mNSCLC - L2 - PDL1 positive

Comparator: vs docetaxel; vs osimertinib; vs Standard of Care (SoC);
Risk of bias: low; some concerns; high; NA;